Analyst Reco. Magenta Therapeutics

Equities

MGTA

US55910K1088

Market Closed - Nasdaq Other stock markets 04:00:00 2026-01-15 pm EST			5-day change	1st Jan Change
44.00 ^USD	-4.95%		+15.42%	+293.08%

23-09-11	Magenta Therapeutics, Inc.(NasdaqCM:MGTA) dropped from NASDAQ Composite Index	CI
23-09-10	Dianthus Therapeutics, Inc. completed the acquisition of Magenta Therapeutics, Inc. from a group of shareholders in a reverse merger transaction.	CI

Analyst Reco.

23-02-28	HC Wainwright Initiates Magenta Therapeutics at Neutral	MT
23-01-26	BTIG Downgrades Magenta Therapeutics to Neutral From Buy	MT
23-01-26	Cowen Downgrades Magenta Therapeutics to Market Perform From Outperform	MT
23-01-26	Wedbush Downgrades Magenta Therapeutics to Neutral From Outperform on MGTA-117 Safety Issues, Lowers Price Targe to $1 From $3	MT
22-12-21	BTIG Lowers Price Target on Magenta Therapeutics to $3 From $6, Maintains Buy Rating	MT
22-12-20	Wedbush Adjusts Magenta Therapeutics Price Target to $3 From $6, Maintains Outperform Rating	MT
22-08-25	Goldman Sachs Downgrades Magenta Therapeutics to Neutral From Buy, Maintains $2 Price Target	MT
22-05-24	Goldman Sachs Adjusts Price Target for Magenta Therapeutics to $2 From $3, Keeps Buy Rating	MT
22-05-16	Wedbush Adjusts Magenta Therapeutics Price Target to $6 From $7, Maintains Outperform Rating	MT
22-04-18	Mizuho Securities Adjusts Magenta Therapeutics' Price Target to $8 From $17, Reiterates Buy Rating	MT
22-04-18	BTIG Adjusts Magenta Therapeutics' Price Target to $6 From $10, Reiterates Buy Rating	MT
22-04-14	Wedbush Adjusts Magenta Therapeutics Price Target to $7 From $9, Maintains Outperform Rating	MT
22-03-08	Wedbush Adjusts Magenta Therapeutics Price Target to $9 From $14, Maintains Outperform Rating	MT
22-01-24	B. Riley Lowers Magenta Therapeutics' Price Target to $6 from $13 After Revising Cost Capital Assumptions, Keeps Buy Rating	MT
22-01-11	Wedbush Trims Magenta Therapeutics' Price Target to $14 From $15, Keeps Outperform Rating	MT
22-01-06	Goldman Sachs Lifts Magenta Therapeutics to Buy From Neutral, Price Target to $8 From $7	MT
21-11-08	B. Riley Lowers Magenta Therapeutics' PT to $13 from $19 on Lower Peak Sales for MGTA-145, Keeps Buy Rating	MT
21-11-04	Wedbush Adjusts Price Target for Magenta Therapeutics to $15 From $20, Maintains Outperform Rating	MT
21-08-03	Analyst recommendations: Applied Industrials, Fastenal, Meggit, Planet Fitness, Krispy Kreme...
21-08-03	MAGENTA THERAPEUTICS : JPMorgan Cuts Magenta Therapeutics to Neutral From Overweight, Price Target to $7 From $16	MT
21-07-22	MAGENTA THERAPEUTICS : B. Riley Lowers Magenta Therapeutics' PT to $19 from $21, Updates Model due to Potential Clinical Trial Delay; Keeps Buy Rating	MT
21-07-21	MAGENTA THERAPEUTICS : Wedbush Adjusts Price Target on Magenta Therapeutics to $20 From $22, Keeps Outperform Rating	MT
21-06-29	MAGENTA THERAPEUTICS : Cantor Fitzgerald Starts Magenta Therapeutics at Overweight With $20 Price Target	MT
21-06-15	MAGENTA THERAPEUTICS : BTIG Starts Magenta Therapeutics at Buy With $20 Price Target	MT
21-05-18	MAGENTA THERAPEUTICS : B. Riley Starts Magenta Therapeutics at Buy with $21 Price Target	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages MarketScreener Editorial Features MarketScreener Strategies Trading Ideas

Analyst Reco. Magenta Therapeutics

Equities

MGTA

US55910K1088

Analyst Reco.

Filters